Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2


TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals   Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Monday, May 2, 2022, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the fourth quarter and year ended December 31, 2021. 


Galmed Pharmaceuticals Logo


Conference Call & Webcast:

Monday May 2, 2022, 8:30 AM ET
Toll Free:                              1-877-425-9470
Toll/International:                  1-201-389-0878
Israel Toll Free:                    1 809 406 247
Conference ID:                     13727793

Replay Dial-In Numbers

Toll Free:                                1-844-512-2921
Toll/International:                   1-412-317-6671
Replay Pin Number:               13727793
Replay Start:                          Monday May 2, 2022, 11:30 AM ET
Replay Expiry:                        Monday May 16, 2022, 11:59 PM ET

About Aramchol and Non-alcoholic Steatohepatitis (NASH)

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.

Cision View original content:

SOURCE Galmed Pharmaceuticals Ltd.

Company Codes: Berlin:GPH, NASDAQ-SMALL:GLMD, Frankfurt:GPH, Stuttgart:GPH

Back to news